Forschung, Karl Landsteiner Privatuniversität, Uniklinikum

Research projects

Forschung, Karl Landsteiner Privatuniversität, KRIS

Research portal KRIS

KL Research Information System

The research portal KRIS (Karl Landsteiner information system) presents the entire research output of researchers at Karl Landsteiner University of Health Sciences. The portal facilitates searches for research outputs, people and organisational units. Publications, research projects, awards and memberships are all presented in a clear and consistent way on KRIS. KRIS enables experts to network and ensures the visibility of public research activities.
The following overview provides a brief outline of the latest projects. For more information, click on the link for KRIS.

Overview of KL research projects

The Role of NKG2D-Ligands in Clinical Oncology

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Active

Prevalence, costs, and impact of anticancer treatment and Palliative Care Services at the end of life of patients with advanced lung cancer in Lower Austria

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Active

Unraveling the pathogenesis to improve treatment of cancer metastasis

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Active

Biomarker- based therapeutic prevention of bone metastases in breast cancer: Defining the pathophysiologic impact of the endosteal niche

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished

Retrospektive Analyse der Inzidenz und der Kosten medikamentöser Antitumortherapie (Chemotherapie, „Small Molecules“, zielgerichtete Antikörpertherapie, Immuncheckpoint-Inhibitoren) in der letzten Lebensphase bei PatientInnen mit soliden Tumoren in Krems

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished
  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished

STAT3 isoforms in hematopoietic disorders

  • Department of Pharmacology
  • Department of Molecular Oncology and Hematology
  • Division of Internal Medicine 2 (University Hospital Krems)
  • Molecular Oncology / Hematology
EFRE Logo

JunB in multiple myeloma

  • Department of Molecular Oncology and Hematology
  • Division of Internal Medicine 2 (University Hospital Krems)
  • Molecular Oncology / Hematology

Uncovering new checkpoints in natural killer cells to prevent breast cancer metastasis

  • Department of Pharmacology
  • Division of Internal Medicine 2 (University Hospital Krems)

Red flags: Improving knowledge of serious pathologies

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Bachelor's Programme Medical Science
  • Division of Orthopaedics and Traumatology (University Hospital Krems)
  • Finished

Ein 3D Model des Immun-Knochenmilieus zur Metastasenforschung

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Active

Investigating the role of MIC-A and MIC-B on tumor cells

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished

Targeting Transcription factors for cancer therapy utilizing PROteolysis-TArgeting Chimera (PROTACs)

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished

Evaluierung des Gesamtüberlebens sowie der Einbindung von Palliativ Care bei PatientInnen mit fortgeschrittenem nicht kleinzelligem Bronchialkarzinom im Stadium IV seit 2008 am Universitätsklinikum Krems

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished

Untersuchung der Effekte von Immun-Checkpoint Inhibitoren auf den Knochenumbau.

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished

Biomarker- based therapeutic prevention of bone metastases in breast cancer. Defining the pathophysiologic impact of the endosteal niche

  • Molecular Oncology / Hematology
  • Division of Internal Medicine 2 (University Hospital Krems)
  • Department of Molecular Oncology and Hematology

Tumor Cachexia

  • Division of Internal Medicine 2 (University Hospital Krems)
  • Finished

JAK2 inhibitors and the innate immune response in mutant CALR-driven MPNs

  • Department of Pharmacology
  • Department of Molecular Oncology and Hematology
  • Division of Internal Medicine 2 (University Hospital Krems)
  • Molecular Oncology / Hematology
EFRE Logo

ACCESS POINT Oncology

  • Department of Molecular Oncology and Hematology
  • Division of Internal Medicine 2 (University Hospital Krems)
  • Molecular Oncology / Hematology
  • Department of Pharmacology